Barriers to Timely Follow-up for Heart Failure Hospitalization
Researchers examine patient barriers when receiving follow-up for heart failure hospitalization.
Heart Failure Information Center
Risk Model May Predict Stroke in Patients With HFpEF Without AF
Researchers sought to determine the rate of stroke in patients with heart failure with preserved ejection fraction without atrial fibrillation.
Latest 2023 FDA Approvals
Recent FDA approvals include treatments for postpartum depression, RSV in infants, pediatric constipation, metastatic colorectal cancer, and iron deficiency.
Increasing Daily Step Counts Tied to Improved Heart Failure Outcomes
Self-reported health status better for patients increasing step counts over 12 weeks.
Cardiac Amyloidosis: Tips For Early Recognition and Treatment
Cardiac amyloidosis is underrecognized in patients with heart failure; however, recent improvements in the understanding of this disease have led to developments in diagnosis and treatment.
Obesity Linked to Lower Short-Term Mortality in Patients With HF With Well-Nourished Status
Researchers studied the effect of nutritional status on the association between obesity and mortality among patients with acute heart failure.
FDA Approves Inpefa for the Treatment of Heart Failure
Inpefa is expected to be available by the end of June 2023.
Hemodynamic Monitoring Beneficial for Chronic Heart Failure
Hemodynamic monitoring improved Kansas City Cardiomyopathy Questionnaire with CardioMEMS-HF system vs standard care
Farxiga Approval Expands Use to More Patients With Heart Failure
Dapagliflozin is sodium-glucose cotransporter 2 inhibitor.
Risk for CVD, Heart Failure Increased Among Black Patients With Gout
Researchers studied the effect of gout on cardiovascular events, including CVD and heart failure, in a Black urban population.
Dapagliflozin Lowers Cardiovascular Risks, Uric Acid Regardless of Gout Status
Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials.
SGLT2 Inhibitor Use in Case of Acute Decompensated Heart Failure With Edema
Case demonstrates initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in a patient with type 2 diabetes and heart failure.
Rural Residence Tied to Higher Risk for Heart Failure for Women, Black Men
Findings persist after adjusting for cardiovascular risk factors and socioeconomic status.
Heart Failure Mortality Lower With Healthier Food Environment
Lower county food insecurity percentage, higher county food environment index linked to lower heart failure mortality rate.
SGLT-2 Inhibitors Show Benefit in Heart Failure With Preserved Ejection Fraction
Investigators conducted a meta-analysis of randomized controlled trials on the effect of SGLT-2 inhibitors on patients with HFpEF.
Interdisciplinary Panel Issues Consensus Document for Managing Hyperkalemia
A committee of nephrologists and cardiologists developed 6 recommendations to improve hyperkalemia management.
Physical Function in Older Adults Linked to CV Event Risk
Low or intermediate score on Short Physical Performance Battery linked to increased risks for composite, individual CVD outcomes.
Rates of Cardiovascular Risk Factors, Disease Projected to Rise by 2060
In the US, prevalence of CV risk factors and disease set to decrease for Whites and increase for racial/ethnic minorities.
Risk for Cardiovascular Disease Increased for Adult Cancer Survivors
Risk for CVD, heart failure, and stroke significantly increased after adjustment for cardiovascular risk factors.
Risk for Hospitalization for Heart Failure Down With SGLT-2i Treatment for T2D
Researchers conducted a population-based cohort study involving patients with T2D aged 18 years and older initiating treatment with SGLT-2i or metformin.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Heart Failure Information Center
Loading... 
Loading...